Sep. 7 at 4:54 PM
$MGTX It’s amazing how little attention and/or credit that prospective investors have given to Meira for their partnership with Hologen. When the deal was announced, both
Hologen & MeiraGTx said it represented the first ever neuro-AI clinical drug development company and that it would “transform the discovery and development of therapies targeting CNS circuitry in neurodegenerative and neuropsychiatric disorders”. Why did they choose to focus in this area? Because of its massive scale. According to ChatGPT, a conservative global TAM for this space in terms of annual revenue potential is between
$110B-
$130B. A moderate TAM is
$200B -
$350B and an aggressive TAM is
$600B -
$1.5T. While these numbers are industry wide for the neuroscience market and not just drug sales, the point is clear that even if the JV yeilds a "tiny" amount of success across drug development, manufacturing, licensing, etc, Meira's valuation will explode.
